Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2Not yet recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Pancreatic Neoplasms 11Neoplasms 5Stomach Neoplasms 2Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Metastatic Pancreatic Adenocarcinoma 2Head and Neck Neoplasms 2Glioma 2Colorectal Neoplasms 2Biliary Tract Neoplasms 2Weight Loss 1Triple Negative Breast Neoplasms 1Solid Tumor 1Refractory Solid Tumors 1Pseudomyxoma Peritonei 1Pancreatic cancer, adult 1Pancreatic Diseases 1Oligodendroglioma 1Neoplasms, Cystic, Mucinous, and Serous 1Metastatic Adenocarcinoma of the Pancreas 1Mesothelioma 1Malignant Solid Neoplasm 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Pancreatic Carcinoma(LAPC) 1Gliosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Endocrine Gland Neoplasms 1Disease 1Digestive System Neoplasms 1

Interventions

Cisplatin 117Oxaliplatin 111Fluorouracil 100Capecitabine 90Docetaxel 69Leucovorin 60Irinotecan 57Paclitaxel 49S 1 (combination) 38pembrolizumab 35Trastuzumab 31Radiotherapy 25Bevacizumab 20Nivolumab 19Epirubicin 19titanium silicide 18Surgical Procedures, Operative 17Carboplatin 17Ramucirumab 16Cetuximab 15Gastrectomy 13apatinib 12Everolimus 12Gemcitabine 11Albumin-Bound Paclitaxel 10Neoadjuvant Therapy 8Folfox protocol 8Drug Therapy 8Chemotherapy, Adjuvant 8Radiation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Stomach Neoplasms × irinotecan sucrosofate × Clear all
NCT04088786 2022-05-06

Phase I Trial HIPEC With Nal-irinotecan

Stony Brook University

Phase 1 Completed
18 enrolled
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma, Mucinous, Mesothelioma, Pseudomyxoma Peritonei, Stomach Neoplasms, Colorectal Neoplasms, Neoplasms, Cystic, Mucinous, and Serous

NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡